Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5506705 | 0.88 | KEAP1 (0.38) | KEAP1NFE2L2LMNAMMP2MMP13 | |
| SCHEMBL7956674 | 0.88 | KEAP1 (0.40) | KEAP1NFE2L2LMNAMMP2MMP13 | |
| SCHEMBL5928160 | 0.87 | KEAP1 (0.38) | KEAP1NFE2L2LMNAMMP2MMP13 | |
| SCHEMBL5031172 | 0.87 | KEAP1 (0.36) | KEAP1NFE2L2LMNAMMP2MMP13 | |
| SCHEMBL7955245 | 0.87 | KEAP1 (0.40) | KEAP1NFE2L2LMNAMMP2MMP13 | |
| SCHEMBL5689205 | 0.87 | KEAP1 (0.40) | KEAP1NFE2L2LMNAMMP2MMP13 | |
| SCHEMBL7953042 | 0.85 | KEAP1 (0.39) | KEAP1NFE2L2LMNAMMP2MMP13 | |
| SCHEMBL7959894 | 0.85 | KEAP1 (0.38) | KEAP1NFE2L2LMNAMMP2MMP13 | |
| SCHEMBL5691171 | 0.84 | ALDH1A1 (0.35) | KEAP1NFE2L2LMNAMMP2MMP13 | |
| SCHEMBL7765077 | 0.84 | MMP2 (0.41) | KEAP1NFE2L2LMNAMMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060240410-A1 | Retroviral protease inhibitor combinations | G.D. SEARLE & CO. (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1649871-A1 | Retroviral protease inhibitor combinations | G.D. Searle LLC. (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-0762880-B1 | RETROVIRAL PROTEASE INHIBITOR COMBINATIONS | SEARLE LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6861539-B1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6673822-B2 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-20030207813-A1 | Retroviral protease inhibitor combinations | G.D. SEARLE (US) | 2003-11-06 | — | — | US | disclosed |
| US-20030130202-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-07-10 | — | — | US | disclosed |
| EP-0815124-B1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-0813542-B1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6316496-B1 | FOR THERAPY OF RETROVIRAL INFECTION; PROPHYLAXIS OF REPLICATION OF RETROVIRUS, THERAPY OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | G. D. SEARLE & CO. | 2001-11-13 | — | — | US | disclosed |
| US-6310080-B1 | TREATING RETROVIRAL INFECTIONS SUCH AS AIDS | G. D. SEARLE & CO. | 2001-10-30 | — | — | US | disclosed |
| US-6214861-B1 | ENZYME INHIBITOR; VIRICIDES | G.D. SEARLE & CO. | 2001-04-10 | — | — | US | disclosed |
| US-6140505-A | REACTING A BENZO FUSED HETEROCYCLIC COMPOUND WITH AN SO3 COMPLEX IN THE PRESENCE OF A WATER IMMISCIBLE, NON-REACTIVE SOLVENT, AT A TEMPERATURE OF FROM ABOUT 0 TO ABOUT 75 DEGREES C., COOLING AND THEN ADDING OXALYL HALIDE. | G. D. SEARLE & CO. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6100277-A | ADMINISTERING MIXTURE OF FIRST AND SECOND RETROVIRAL PROTEASE INHIBITOR WHEREIN SAID SECOND RETROVIRAL PROTEASE INHIBITOR IS EFFECTIVE AGAINST VIRAL STRAIN(S) RESISTANT TO FIRST INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-08 | — | — | US | disclosed |
| US-5972989-A | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5968970-A | TREATMENT OF HIV | G. D. SEARLE & COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0815124-A1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028465-A1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996028463-A1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207813-A1 | Retroviral protease inhibitor combinations | PREP, SERPINB1, PRSS1 | KEAP1 2475/4885NFE2L2 3935/4885LMNA 2553/4885 |
| US-20030130202-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | KEAP1 3833/4885NFE2L2 4397/4885LMNA 3109/4885 |
| US-20060189611-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | KEAP1 4428/4885NFE2L2 4412/4885LMNA 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.